Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases

Table 2 Highlights of ongoing clinical trials (National Cancer Institute) regarding systemic treatment for metastatic colorectal cancer

Protocol ID	Principle investigator	Phase, purpose, and relevance
NCT02149108	Boehringer Ingelheim	Phase III study of salvage nindetanib
NCT02305758	AbbVie	Phase IIstudy of first-line veliparib (PARP inhibitor) added to FOLFIRI +/- bmab
NCT02060188	Bristol-Myers Squibb	Phase II study of nivolumab (anti-PD1 antibody) +/- Ipilimumab in recurrent and microsatellite high (MSI-H) colon cancer
NCT02119676	Incyte	Phase II study of salvage ruxolitinib (a JAK1 and JAK2 inhibitor) in combination with regorafenib
NCT02260440	University of Pittsburgh	Phase II study of salvage pembrolizumab (anti-PD1) in combination with azacitidine
NCT01661972	Duke University Medical Center	Phase I/II study of capecitabine plus aflibercept (“X-TRAP study”)
NCT02168777	Bayer	Phase I/II study of remafetinib with regorafenib
NCT02079740	National Cancer Institute, United States	Phase Ib/II study of trametinib (a MEK inhibitor) and navitoclax (BCL-2 Family Inhibitor) in KRAS mutant advanced tumors
NCT00940316	Genentech, OSI Pharmaceuticals, Amgen	Phase I/II study of dual epidermal growth factor receptor inhibition With Erlotinib and Panitumumab with or without chemotherapy
NCT01985763	Mt. Sinai School of Medicine, New York City	Phase I/II study of first line genistein (a soy derivative that interrupts Wnt signaling) in addition to standard regimens
NCT01471353	University of Florida	Phase II study of salvage sorafenib plus capecitabine (SorCape)
NCT01750918	GlaxoSmithKline	Phase I/II study of trametinib and dabrafenib in combination with panitumumab in BRAF-mutation V600E colorectal cancer and in patients with resistance to prior anti-EGFR therapy